Literature DB >> 25006812

The role of patient expectancy in placebo and nocebo effects in antidepressant trials.

Bret R Rutherford1, Melanie M Wall, Andrew Glass, Jonathan W Stewart.   

Abstract

OBJECTIVE: To determine whether patient expectancy plays a role in observed placebo and nocebo effects in 2 clinical trials.
METHOD: Data were reanalyzed from 2 fluoxetine-discontinuation studies conducted from March 1990 to September 1992 and from May 1997 to December 2002. The 673 outpatients included were aged 18-65 years with DSM-III-R major depressive disorder (MDD), responded to 12-week duration open treatment, and were randomized to continued fluoxetine or placebo for an additional year. Participants in 1 of the included studies received a fixed dose of fluoxetine 20 mg daily, while the second study utilized flexible fluoxetine doses up to 60 mg daily. Mixed effects longitudinal models determined whether the possible randomization to placebo at 12 weeks resulted in significant depressive symptom worsening across treatments. Correlations were computed between early symptom change (weeks 1-3 of open treatment) and postrandomization symptom change (weeks 13-16 following randomization).
RESULTS: Participants continuing to receive fluoxetine and those switched to placebo had significantly higher mean Hamilton Depression Rating Scale (HDRS) scores immediately postrandomization compared to the final weeks of open treatment (P < .001 for both fluoxetine- and placebo-treated patients). In both studies, early HDRS change was significantly correlated with postrandomization HDRS change for patients receiving fluoxetine (r = -0.46, P < .001) as well as placebo (r = -0.48, P < .001).
CONCLUSIONS: The possibility of receiving placebo following 12 weeks of open fluoxetine was associated with significant symptom worsening in 2 large fluoxetine discontinuation studies. Worsening depression scores following randomization were significantly associated with the degree of improvement participants experienced during weeks 1-3 of open treatment. These results suggest that treatment changes influence patients' expectations of improvement, which, in turn, affect their depressive symptoms. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25006812      PMCID: PMC4221413          DOI: 10.4088/JCP.13m08797

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  28 in total

Review 1.  The placebo effect: dissolving the expectancy versus conditioning debate.

Authors:  Steve Stewart-Williams; John Podd
Journal:  Psychol Bull       Date:  2004-03       Impact factor: 17.737

2.  Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo.

Authors:  J W Stewart; F M Quitkin; P J McGrath; J Amsterdam; M Fava; J Fawcett; F Reimherr; J Rosenbaum; C Beasley; P Roback
Journal:  Arch Gen Psychiatry       Date:  1998-04

Review 3.  Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

Authors:  Mark Sinyor; Anthony J Levitt; Amy H Cheung; Ayal Schaffer; Alex Kiss; Yekta Dowlati; Krista L Lanctôt
Journal:  J Clin Psychiatry       Date:  2010-01-26       Impact factor: 4.384

4.  Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study.

Authors:  J D Amsterdam; J Fawcett; F M Quitkin; F W Reimherr; J F Rosenbaum; D Michelson; M Hornig-Rohan; C M Beasley
Journal:  Am J Psychiatry       Date:  1997-07       Impact factor: 18.112

5.  A randomized, prospective pilot study of patient expectancy and antidepressant outcome.

Authors:  B R Rutherford; S M Marcus; P Wang; J R Sneed; G Pelton; D Devanand; N Duan; S P Roose
Journal:  Psychol Med       Date:  2012-09-13       Impact factor: 7.723

6.  Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.

Authors:  Arif Khan; Russell L Kolts; Michael E Thase; K Ranga Rama Krishnan; Walter Brown
Journal:  Am J Psychiatry       Date:  2004-11       Impact factor: 18.112

7.  Identification of true drug response to antidepressants. Use of pattern analysis.

Authors:  F M Quitkin; J G Rabkin; D Ross; J W Stewart
Journal:  Arch Gen Psychiatry       Date:  1984-08

Review 8.  Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

Authors:  George I Papakostas; Maurizio Fava
Journal:  Eur Neuropsychopharmacol       Date:  2008-09-26       Impact factor: 4.600

Review 9.  A model of placebo response in antidepressant clinical trials.

Authors:  Bret R Rutherford; Steven P Roose
Journal:  Am J Psychiatry       Date:  2013-07       Impact factor: 18.112

10.  Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.

Authors:  J F Rosenbaum; M Fava; S L Hoog; R C Ascroft; W B Krebs
Journal:  Biol Psychiatry       Date:  1998-07-15       Impact factor: 13.382

View more
  9 in total

1.  Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder.

Authors:  Aimee M Hunter; Ian A Cook; Molly Tartter; Simi K Sharma; Gregory D Disse; Andrew F Leuchter
Journal:  Psychopharmacology (Berl)       Date:  2015-08-29       Impact factor: 4.530

Review 2.  Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?

Authors:  Pieter-Jan Carpentier; Frances R Levin
Journal:  Harv Rev Psychiatry       Date:  2017 Mar/Apr       Impact factor: 3.732

3.  Placebo Response in Rheumatoid Arthritis Clinical Trials.

Authors:  Katie Bechman; Mark Yates; Sam Norton; Andrew P Cope; James B Galloway
Journal:  J Rheumatol       Date:  2019-05-01       Impact factor: 4.666

4.  Changes in typical beliefs in response to complicated grief treatment.

Authors:  Natalia A Skritskaya; Christine Mauro; Angel Garcia de la Garza; Franziska Meichsner; Barry Lebowitz; Charles F Reynolds; Naomi M Simon; Sidney Zisook; M Katherine Shear
Journal:  Depress Anxiety       Date:  2019-12-05       Impact factor: 6.505

5.  Specific expectancies are associated with symptomatic outcomes and side effect burden in a trial of chamomile extract for generalized anxiety disorder.

Authors:  John R Keefe; Jay Amsterdam; Qing S Li; Irene Soeller; Robert DeRubeis; Jun J Mao
Journal:  J Psychiatr Res       Date:  2016-09-30       Impact factor: 4.791

6.  A pilot randomized controlled trial of hearing aids to improve mood and cognition in older adults.

Authors:  Katharine K Brewster; Martina Pavlicova; Alexandra Stein; Mei Chen; Chen Chen; Patrick J Brown; Steven P Roose; Ana H Kim; Justin S Golub; Adam Brickman; Jessica Galatioto; Megan Kuhlmey; Bret R Rutherford
Journal:  Int J Geriatr Psychiatry       Date:  2020-04-23       Impact factor: 3.485

7.  Ethical considerations in placebo-controlled randomised clinical trials.

Authors:  Kenneth R Kaufman
Journal:  BJPsych Open       Date:  2015-06-30

8.  Significance of Participants' Expectations in Managing the Placebo Effect in Antidepressant Research.

Authors:  Marko Curkovic; Andro Kosec
Journal:  Front Psychiatry       Date:  2019-10-01       Impact factor: 4.157

9.  The Importance of Patient Expectations: A Mixed-Methods Study of U.S. Psychiatrists.

Authors:  Maayan N Rosenfield; Michael H Bernstein
Journal:  Front Psychiatry       Date:  2021-12-03       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.